News Search Results
Apr 11, 2025, 13:00 ET WesternU COMP and COMP-Northwest named Tier 1 medical school for primary care for second consecutive year
Calif. and Lebanon, Ore., is an independent nonprofit health professions university, conferring degrees in biotechnology and pharmaceutical sciences, dental medicine, medical sciences, nursing, optometry, osteopathic medicine, pharmacy, physical therapy, physician
More news about: Western University of Health Sciences
Apr 11, 2025, 12:31 ET Global Times: Believing in China, believing in tomorrow
China's action.From launching pilot projects to expand opening-up in the fields of value-added telecommunications and biotechnology, to support domestic and foreign-funded enterprises equally in participating in large-scale equipment upgrades, consumer goods trade-in and other
More news about: Global Times
Apr 11, 2025, 10:23 ET ZINZINO AB (PUBL.): Zinzino acquires Valentus Global to increase distribution power in Europe
strategically important step in Zinzino's growth plans, which focus on improving personal health and well-being on a global scale with innovative biotechnology and a pioneering product portfolio marketed through direct sales. Valentus Global Inc. is a direct selling company based in Delaware,
More news about: Zinzino
Apr 11, 2025, 10:13 ET ZINZINO AB (PUBL.): Zinzino acquires Valentus Global to increase distribution power in Europe
strategically important step in Zinzino's growth plans, which focus on improving personal health and well-being on a global scale with innovative biotechnology and a pioneering product portfolio marketed through direct sales. Valentus Global Inc. is a direct selling company based in Delaware,
More news about: Zinzino
Apr 11, 2025, 09:00 ET IMDELLTRA® DEMONSTRATED SUPERIOR OVERALL SURVIVAL IN SMALL CELL LUNG CANCER
to help millions of patients in their fight against some of the world's toughest diseases. More than 40 years ago, Amgen helped to establish the biotechnology industry and remains on the cutting-edge of innovation, using technology and human genetic data to push beyond what's known today. Amgen is advancing
More news about: Amgen
Apr 11, 2025, 08:00 ET Novonesis Poised to Accelerate National Security Commission Priorities on Biotechnology
importance of the National Security Commission on Emerging Biotechnology (NSCEB) report as a pivotal milestone in charting a bold path forward for American biotechnology. Novonesis applauds the NSCEB's deep investigation of unlocking U.S.-led biotechnology in the Fourth Industrial Revolution.
More news about: Novonesis
Apr 11, 2025, 05:45 ET Class Action Filed Against Sana Biotechnology, Inc. (SANA) Seeking Recovery for Investors - Contact Levi & Korsinsky
April 11, 2025 /PRNewswire/ -- Levi & Korsinsky, LLP notifies investors in Sana Biotechnology, Inc. ("Sana Biotechnology, Inc." or the "Company") (NASDAQ: SANA) of a class action securities lawsuit.
More news about: Levi & Korsinsky, LLP
Apr 11, 2025, 05:45 ET Class Action Filed Against ICON Public Limited Company (ICLR) Seeking Recovery for Investors - Contact Levi & Korsinsky
insufficient to shield the Company from the adverse effects of a significant market downturn; (c) the requests for proposals ICON received from its biotechnology customers during the Class Period were used in substantial part as price discovery tools, and thus were not indicative of underlying client demand;
More news about: Levi & Korsinsky, LLP
Apr 10, 2025, 22:22 ET CCV Capital's Founding Managing Partner Wei Zhou Attends the 2025 Harvard College China Forum
political, and academic communities worldwide gathered to engage in in-depth discussions on frontier topics such as international relations, economics, biotechnology, and artificial intelligence. Distinguished guests included Kevin Rudd, former Prime Minister of Australia;
More news about: CCV Capital
Apr 10, 2025, 18:15 ET Halozyme Announces FDA Approval of argenx's VYVGART® Hytrulo Prefilled Syringe Co-Formulated with ENHANZE® for Self-Injection for Generalized Myasthenia Gravis and Chronic Inflammatory Demyelinating Polyneuropathy
commercialized products across more than 100 global markets, Halozyme has licensed its ENHANZE® technology to leading pharmaceutical and biotechnology companies including Roche, Takeda, Pfizer, Janssen, AbbVie, Eli Lilly, Bristol-Myers Squibb, argenx, ViiV Healthcare, Chugai Pharmaceutical and
More news about: Halozyme Therapeutics, Inc.
Apr 10, 2025, 18:09 ET Oncolytics Biotech® Funds Pelareorep's Ongoing Clinical Development with a Share Purchase Agreement in Partnership with Alumni Capital
qualification under the securities laws of any such jurisdiction. About Oncolytics Biotech Inc. Oncolytics is a clinical-stage biotechnology company developing pelareorep, an intravenously delivered immunotherapeutic agent. Pelareorep has demonstrated promising results in two randomized
More news about: Oncolytics Biotech® Inc.
Apr 10, 2025, 13:09 ET Oerth Bio Publishes Landmark Study Demonstrating the First Application of PROTACs in Agriculture
more selective, environmentally friendly, and overcome current resistance challenges. "Oerth Bio's work demonstrates how cutting-edge biotechnology platforms can be reimagined to solve some of agriculture's most urgent challenges. This publication is a key proof point for Leaps by Bayer's mission
More news about: Oerth Bio
Apr 10, 2025, 13:00 ET Immunic, Inc. Announces Closing of $5.1 Million Registered Direct Offering, Led by Aberdeen Investments
Immunic, Inc. ("Immunic" or the "Company") (Nasdaq: IMUX), a biotechnology company developing a clinical pipeline of orally administered, small molecule therapies for chronic inflammatory and autoimmune diseases, today
More news about: Immunic, Inc.
Apr 10, 2025, 12:14 ET Professor Niazi Challenges the 2024 Chemistry Nobel Prize that the 3D Protein Structure cannot be predicted, refuting claims of Rosetta and AlphaFold
Quantum mechanics paradox in protein structure prediction: Intrinsically linked to sequence yet independent of it, Computational and Structural Biotechnology Reports, Volume 2, 2025, 100039, ISSN 2950-3639, https://doi.org/10.1016/j.csbr.2025.100039.
More news about: Professor Sarfaraz K. Niazi
Apr 10, 2025, 12:00 ET ICON plc (ICLR) Investors Who Lost Money Have Opportunity to Lead Securities Fraud Lawsuit
offerings were insufficient to shield the Company from the adverse effects of a significant market downturn; (3) that the RFPs ICON received from its biotechnology customers during the Class Period were used in substantial part as price discovery tools, and thus were not indicative of underlying client demand;
More news about: Glancy Prongay & Murray LLP
Apr 10, 2025, 11:28 ET Rubin and Rudman Elevates Lauren DeMatteo to Partner
Rubin and Rudman serves national and international companies, including large public companies and closely held businesses; real estate developers; biotechnology, pharmaceutical and medical device makers; regulated industries, public entities and municipalities; insurance companies and their insureds; educational
More news about: Rubin and Rudman
Apr 10, 2025, 10:01 ET Global Organ on a Chip Market Valuation is Poised to Surpass 2,238.28 Million by 2033 | Astute Analytica
DiscoveryToxicology ResearchOthersBy End Users Academic and Research InstitutesPharmaceutical & Biotechnology CompaniesOthersBy Region North AmericaEurope
More news about: Astute Analytica
Apr 10, 2025, 09:00 ET Ginkgo Bioworks Teams Up with Partners on ARPA-H Project to Stabilize Pharmaceutical Supply Chains - Using Amber Waves of Grain
is innovation, and we are committed to accelerating the bio-manufacturing process and delivering new products that address global challenges in biotechnology. Our proprietary strain-free discovery platform, seamlessly integrated with scaled production, enables us to iterate, optimize, and launch
More news about: Ginkgo Bioworks
Apr 10, 2025, 08:37 ET Biocon Biologics Announces U.S. FDA Approval for Jobevne™, Biosimilar Bevacizumab, Expanding Its Oncology Portfolio
international interest rates, change in laws and regulations that apply to the Indian and global biotechnology and pharmaceuticals industries, increasing competition in and the conditions of the Indian and global biotechnology and pharmaceuticals industries, changes in political conditions in India
More news about: Biocon Biologics Ltd.
Apr 10, 2025, 08:00 ET Nona Biosciences and Atossa Therapeutics Partner to Discover Next-Generation Antibody Therapies for Breast Cancer
Mass., April 10, 2025 /PRNewswire/ -- Nona Biosciences, a global biotechnology company providing integrated solutions from "Idea to IND" (I to ITM), ranging from target validation and antibody discovery through preclinical
More news about: Nona Biosciences
Apr 10, 2025, 08:00 ET South Rampart Pharma Strengthens Board with Appointment of Ochsner Health CEO Pete November
April 10, 2025 /PRNewswire/ -- South Rampart Pharma, Inc. ("South Rampart" or the "Company"), a clinical-stage biotechnology company advancing best-in-class, non-opioid pain therapeutics, today announced the appointment of Pete November,
More news about: South Rampart Pharma
Apr 10, 2025, 08:00 ET Philip J. Bergman, DVM, PhD, DACVIM (Oncology) Joins ELIAS Animal Health Scientific Advisory Board
www.eliasanimalhealth.com. About ELIAS Animal HealthELIAS Animal Health is a medical biotechnology company focused on advancing a pipeline of immunotherapies, including an adoptive cell therapy and an oncolytic immunotherapy, for the treatment
More news about: ELIAS Animal Health
Apr 10, 2025, 07:30 ET BrainStorm Cell Therapeutics Submits IND Amendment to FDA, Paving the Way for Phase 3b Trial of NurOwn® in ALS
April 10, 2025 /PRNewswire/ -- BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading biotechnology company developing cutting-edge cell therapies for neurodegenerative diseases, today announced the submission of an Investigational New Drug (IND)
More news about: BrainStorm Cell Therapeutics Inc.
Apr 10, 2025, 07:30 ET Palatin to Present Positive Phase 2b Data for Melanocortin Agonist in Diabetic Kidney Disease at the National Kidney Foundation Spring Meeting
complete clinical trials and submit applications for regulatory approvals, products developed by competing pharmaceutical, biopharmaceutical and biotechnology companies, commercial acceptance of Palatin's products, and other factors discussed in Palatin's periodic filings with the Securities and Exchange
More news about: Palatin Technologies, Inc.
Apr 10, 2025, 07:00 ET Oncolytics Biotech® and Pelareorep Discussed During Recent H.C. Wainwright Key Opinion Leader Event on Oncolytic Immunotherapies in Breast and Pancreatic Cancers
clicking here. About Oncolytics Biotech Inc. Oncolytics is a clinical-stage biotechnology company developing pelareorep, an intravenously delivered immunotherapeutic agent. Pelareorep has demonstrated promising results in two randomized
More news about: Oncolytics Biotech® Inc.